{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gammopathy", "query": { "condition": "Gammopathy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 93, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gammopathy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T14:05:53.727Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04850846", "title": "Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Monoclonal Gammopathy of Undetermined Significance", "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Metformin XR", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-04-27", "completion_date": "2027-07-31", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Brighton", "state": "Massachusetts" }, { "city": "Methuen", "state": "Massachusetts" }, { "city": "Milford", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04850846" }, { "nct_id": "NCT01063907", "title": "A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "KW-2478", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2010-03", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 9, "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01063907" }, { "nct_id": "NCT00132015", "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Nonneoplastic Condition", "Precancerous Condition" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2006-05", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00132015" }, { "nct_id": "NCT00416624", "title": "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" }, { "name": "fatigue assessment and management", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 239, "start_date": "2007-05", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00416624" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT00006362", "title": "PS-341 in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2011-08-03", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Madison, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006362" }, { "nct_id": "NCT00001287", "title": "Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Demyelinating Diseases", "Paraproteinemias" ], "interventions": [ { "name": "intravenous immunoglobulin (IVIg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 60, "start_date": "1990-12", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001287" }, { "nct_id": "NCT02298816", "title": "B-Cell Hematologic Malignancy Vaccination Registry", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Monoclonal Gammopathy of Undetermined Significance", "Multiple Myeloma", "Waldenstrom Macroglobulinemia", "Lymphocytosis", "Lymphoma, Non-Hodgkin", "B-Cell Chronic Lymphocytic Leukemia", "Hematological Malignancies" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2014-08", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298816" }, { "nct_id": "NCT00003082", "title": "Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "monoclonal antibody A27.15", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody E2.3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "1997-12", "completion_date": "2001-02", "has_results": false, "last_update_posted_date": "2010-03-16", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003082" }, { "nct_id": "NCT04727294", "title": "MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma", "Smoldering Multiple Myeloma", "Monoclonal Gammopathy of Undetermined Significance", "Coronavirus" ], "interventions": [ { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "HealthTree Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2021-01-22", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-08-04", "last_synced_at": "2026-06-27T14:05:53.727Z", "location_count": 1, "location_summary": "Lehi, Utah", "locations": [ { "city": "Lehi", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04727294" } ] }